newsfilter
← Latest News
PR Newswire·

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using...